Disc Medicine Inc
Company Profile
Business description
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998.
Contact
321 Arsenal Street
Suite 101
WatertownMA02472
USAT: +1 617 674-9274
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
84
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,775.40 | 87.40 | 1.01% |
CAC 40 | 7,537.57 | 52.09 | -0.69% |
DAX 40 | 23,269.01 | 81.54 | -0.35% |
Dow JONES (US) | 42,581.78 | 374.96 | 0.89% |
FTSE 100 | 8,758.04 | 16.61 | -0.19% |
HKSE | 24,145.11 | 455.98 | 1.92% |
NASDAQ | 19,630.97 | 183.56 | 0.94% |
Nikkei 225 | 38,768.23 | 414.14 | 1.08% |
NZX 50 Index | 12,479.99 | 52.66 | -0.42% |
S&P 500 | 6,025.17 | 57.33 | 0.96% |
S&P/ASX 200 | 8,557.60 | 82.70 | 0.98% |
SSE Composite Index | 3,415.45 | 33.87 | 1.00% |